P144: Persistence of growth-promoting effects in children with achondroplasia up to 7 years: Update from phase 2 extension study with vosoritide*

• Julie Hoover-Fong,
• Melita Irving,
• Carlos Bacino,
• Joel Charrow,
• Carlos Prada,
• Valerie Cormier-Daire,
• Lynda Polgreen,
• Paul Harmatz,
• Sajda Ghani,
• Elena Fisheleva,
• Andrea Low,
• Jonathan Day,
• John Phillips, III,
• Ravi Savarirayan

Affiliations

Julie Hoover-Fong

Johns Hopkins, Department of Pediatrics, Baltimore, MD

Melita Irving

Guy’s and St. Thomas’ NHS Foundation Trust, Evelina Children’s Hospital, London, UK

Carlos Bacino

Baylor College of Medicine, Houston, TX

Joel Charrow

Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

Carlos Prada

Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

Valerie Cormier-Daire

Paris University, Hopital Necker – Enfants Malades, Paris, France

Lynda Polgreen

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, David Geffen School of Medicine – UCLA, CA

Paul Harmatz

UCSF Benioff Children’s Hospital Oakland, Oakland, CA

Sajda Ghani

BioMarin (U.K.) Limited, London, UK

Elena Fisheleva

BioMarin (U.K.) Limited, London, UK

Andrea Low

BioMarin Pharmaceutical, Novato, CA

Jonathan Day

BioMarin (U.K.) Limited, London, UK

John Phillips, III

Vanderbilt University Medical Center, Nashville, TN

Ravi Savarirayan

Murdoch Children’s Research Institute, Royal Children’s Hospital, and University of Melbourne, Parkville, Australia